Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of COR-003 in endogenous Cushing's syndrome
NL-OMON45174Phase 3Active, not recruiting
- Sponsor
- Strongbridge Biopharma
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of levoketoconazole in Cushing's syndrome and Corticotropin adenoma (ACTHoma), sponsored by Strongbridge Biopharma. Primary endpoints: Clinical responder rate at 6 months and Range of effective doses. Started Dec 2014; status: active, not recruiting.
02
Drugs
levoketoconazole
03
Conditions
Cushing's syndromeCorticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on NL-OMON45174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45174.